

Eileen, Actual Sientra Patient
Eileen, Actual Sientra Patient
The unique feature of the AlloX2 provides surgeons easy access to the periprosthetic space without altering any of the other characteristics of a tissue expander. While one does not plan to experience a postoperative complication, a valid question in light of the availability of the AlloX2 is why one would forego utilizing a device that facilitates treatment thereof.
– ARASH MOMENI, MD
Board-certified plastic and reconstructive surgeon | Palo Alto, CA
Obesity (BMI >30) and use of an Acellular Dermal Matrix (ADM) have been identified as major risk factors for seroma4
A seroma increases the risk of major infection in breast reconstruction patients
Clinically relevant infections with poor salvage rates occurred in nearly 1/5 of seroma patients (18.8%)4
With current standard of care, 78% of infections require explantation4
*ADM currently not approved for use in breast surgery. Please refer to product labeling for more information.
Retrospective review of 112 consecutive patients
AlloX2 Stats:
In a clinical study with 40 primary reconstructive patients, the AlloX2 was deemed successful in treating seromas and should be considered a tool for noninvasive treatment of common complications of tissue expander-based breast reconstruction.